252 related articles for article (PubMed ID: 26008846)
1. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
4. Toward a molecular pathologic classification of urothelial carcinoma.
Sjödahl G; Lövgren K; Lauss M; Patschan O; Gudjonsson S; Chebil G; Aine M; Eriksson P; Månsson W; Lindgren D; Fernö M; Liedberg F; Höglund M
Am J Pathol; 2013 Sep; 183(3):681-91. PubMed ID: 23827819
[TBL] [Abstract][Full Text] [Related]
5. A molecular taxonomy for urothelial carcinoma.
Sjödahl G; Lauss M; Lövgren K; Chebil G; Gudjonsson S; Veerla S; Patschan O; Aine M; Fernö M; Ringnér M; Månsson W; Liedberg F; Lindgren D; Höglund M
Clin Cancer Res; 2012 Jun; 18(12):3377-86. PubMed ID: 22553347
[TBL] [Abstract][Full Text] [Related]
6. FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines.
Warrick JI; Walter V; Yamashita H; Chung E; Shuman L; Amponsa VO; Zheng Z; Chan W; Whitcomb TL; Yue F; Iyyanki T; Kawasawa YI; Kaag M; Guo W; Raman JD; Park JS; DeGraff DJ
Sci Rep; 2016 Dec; 6():38531. PubMed ID: 27924948
[TBL] [Abstract][Full Text] [Related]
7. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
[TBL] [Abstract][Full Text] [Related]
8. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.
Marzouka NA; Eriksson P; Rovira C; Liedberg F; Sjödahl G; Höglund M
Sci Rep; 2018 Feb; 8(1):3737. PubMed ID: 29487377
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Sjödahl G; Eriksson P; Liedberg F; Höglund M
J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
[TBL] [Abstract][Full Text] [Related]
10. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtype classification of urothelial carcinoma in Lynch syndrome.
Therkildsen C; Eriksson P; Höglund M; Jönsson M; Sjödahl G; Nilbert M; Liedberg F
Mol Oncol; 2018 Aug; 12(8):1286-1295. PubMed ID: 29791078
[TBL] [Abstract][Full Text] [Related]
12. Urothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data.
de Matos Simoes R; Dalleau S; Williamson KE; Emmert-Streib F
BMC Syst Biol; 2015 May; 9():21. PubMed ID: 25971253
[TBL] [Abstract][Full Text] [Related]
13. Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer.
Iyyanki T; Zhang B; Wang Q; Hou Y; Jin Q; Xu J; Yang H; Liu T; Wang X; Song F; Luan Y; Yamashita H; Chien R; Lyu H; Zhang L; Wang L; Warrick J; Raman JD; Meeks JJ; DeGraff DJ; Yue F
Genome Biol; 2021 Apr; 22(1):105. PubMed ID: 33858483
[TBL] [Abstract][Full Text] [Related]
14. Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.
Al-Ahmadie H; Iyer G
Surg Pathol Clin; 2018 Dec; 11(4):713-723. PubMed ID: 30447837
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
16. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
18. The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.
Heubach J; Monsior J; Deenen R; Niegisch G; Szarvas T; Niedworok C; Schulz WA; Hoffmann MJ
Mol Cancer; 2015 May; 14():108. PubMed ID: 25994132
[TBL] [Abstract][Full Text] [Related]
19. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
20. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
Sjödahl G
Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
